ITG distributes the SurGraft® family of dehydrated human amniotic membrane allografts — clinically validated for chronic wound care, complex surgical applications, and ophthalmic procedures. Every product is shelf-stable, terminally sterilized, and supported by peer-reviewed evidence.
Dehydrated human amniotic membrane allografts derived from full-term healthy Caesarean sections, processed and sterilized via proprietary Surgenex methods. Rich in growth factors, anti-inflammatory proteins, and extracellular matrix components — engineered to drive healing where conventional therapy has failed.
The foundational amniotic membrane allograft — proven in chronic wound care, surgical applications, and complex tissue defects.
Extended-thickness construct providing enhanced scaffold support for more challenging wound environments.
Triple-layer configuration for the most complex wounds — sufficient substance to be sutured, compatible with negative-pressure wound vacs.
Dehydrated amniotic membrane allograft purpose-formulated for corneal repair, reconstruction, and ophthalmic surgical applications.
Average wound area reduction at 8 weeks across 10 patients with chronic non-healing foot ulcers (Wagner Grade 1 & 2). 99.4% reduction in non-diabetic patients, 81.4% in diabetic patients.
Wound area reduction observed within just one week of initial SurGraft® application. Median of 3.5 graft applications. Zero adverse reactions reported across the study.
The amniotic membrane allografts ITG distributes are not emerging research. They are clinically-validated, regulatory-cleared, and supported by peer-reviewed evidence across chronic, surgical, and ophthalmic applications.
Our team can provide product specifications, peer-reviewed citations, regulatory documentation, and country-specific availability for any of the platforms above.
Request Product Information